Vitamin Shoppe Inc. (NYSE:VSI) was downgraded by analysts at JPMorgan Chase & Co. from an “overweight” rating to a “neutral” rating in a report released on Thursday. They currently have a $28.00 price objective on the stock, down from their prior price objective of $33.00. JPMorgan Chase & Co.’s target price would indicate a potential upside of 12.68% from the stock’s previous close.
A number of other brokerages have also issued reports on VSI. Wedbush reissued an “outperform” rating and issued a $39.00 price objective on shares of Vitamin Shoppe in a report on Wednesday, August 3rd. Barclays PLC initiated coverage on shares of Vitamin Shoppe in a report on Thursday, September 22nd. They issued an “equal weight” rating and a $29.00 price objective for the company. Zacks Investment Research lowered shares of Vitamin Shoppe from a “buy” rating to a “hold” rating in a research note on Wednesday, August 3rd. Finally, Jefferies Group reaffirmed a “hold” rating on shares of Vitamin Shoppe in a research note on Thursday, August 4th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating and one has issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $31.92.
Shares of Vitamin Shoppe (NYSE:VSI) opened at 24.85 on Thursday. Vitamin Shoppe has a 12-month low of $24.48 and a 12-month high of $34.41. The stock has a 50 day moving average of $27.03 and a 200 day moving average of $28.75. The company has a market cap of $586.06 million, a price-to-earnings ratio of 14.56 and a beta of 0.55.
Vitamin Shoppe (NYSE:VSI) last announced its quarterly earnings data on Wednesday, August 3rd. The company reported $0.55 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.59 by $0.04. Vitamin Shoppe had a net margin of 3.56% and a return on equity of 11.53%. The firm earned $332.70 million during the quarter, compared to analysts’ expectations of $331.58 million. During the same period in the prior year, the company posted $0.57 EPS. The company’s revenue for the quarter was up 3.2% compared to the same quarter last year. Analysts forecast that Vitamin Shoppe will post $2.17 earnings per share for the current year.
A number of hedge funds have recently modified their holdings of the stock. Gamco Investors INC. ET AL boosted its stake in shares of Vitamin Shoppe by 123.3% in the second quarter. Gamco Investors INC. ET AL now owns 80,600 shares of the company’s stock valued at $2,464,000 after buying an additional 44,500 shares during the period. Emerald Acquisition Ltd. purchased a new stake in shares of Vitamin Shoppe during the second quarter valued at $355,000. KBC Group NV boosted its stake in shares of Vitamin Shoppe by 61.8% in the second quarter. KBC Group NV now owns 56,600 shares of the company’s stock valued at $1,730,000 after buying an additional 21,613 shares during the period. Capital Fund Management S.A. purchased a new stake in shares of Vitamin Shoppe during the second quarter valued at $339,000. Finally, GW&K Investment Management LLC boosted its stake in shares of Vitamin Shoppe by 12.4% in the second quarter. GW&K Investment Management LLC now owns 42,609 shares of the company’s stock valued at $1,303,000 after buying an additional 4,694 shares during the period.
Vitamin Shoppe Company Profile